Global Antibody-drug Conjugates for Tumors Market Growth 2026-2032
Description
The global Antibody-drug Conjugates for Tumors market size is predicted to grow from US$ 3162 million in 2025 to US$ 4386 million in 2032; it is expected to grow at a CAGR of 4.9% from 2026 to 2032.
Antibody drug conjugates (ADCs) are usually made by coupling antibodies to toxin small molecules through linkers. They have the high targeting of antibodies and the high activity of small molecule drugs, making them an emerging targeted therapy that has shown excellent efficacy and potential in the field of tumor treatment and has become a new hotspot in the field of drug research and development.
United States market for Antibody-drug Conjugates for Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Antibody-drug Conjugates for Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Antibody-drug Conjugates for Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Antibody-drug Conjugates for Tumors players cover Roche（Genentech）, Daiichi Sankyo, GSK, Rakuten Medical, ADC Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Antibody-drug Conjugates for Tumors Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates for Tumors sales in 2025, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates for Tumors sales for 2026 through 2032. With Antibody-drug Conjugates for Tumors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates for Tumors industry.
This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates for Tumors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody-drug Conjugates for Tumors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-drug Conjugates for Tumors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates for Tumors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates for Tumors.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates for Tumors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
DNA Damaging Drugs
Tubulin Inhibitors
Other
Segmentation by Application:
Hematological Tumors
Solid Tumors
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Roche（Genentech）
Daiichi Sankyo
GSK
Rakuten Medical
ADC Therapeutics
RemeGen
AbbVie(ImmunoGen)
Pfizer（Seagen)
Takeda
Gilead Sciences
AstraZeneca
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antibody-drug Conjugates for Tumors market?
What factors are driving Antibody-drug Conjugates for Tumors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antibody-drug Conjugates for Tumors market opportunities vary by end market size?
How does Antibody-drug Conjugates for Tumors break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Antibody drug conjugates (ADCs) are usually made by coupling antibodies to toxin small molecules through linkers. They have the high targeting of antibodies and the high activity of small molecule drugs, making them an emerging targeted therapy that has shown excellent efficacy and potential in the field of tumor treatment and has become a new hotspot in the field of drug research and development.
United States market for Antibody-drug Conjugates for Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Antibody-drug Conjugates for Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Antibody-drug Conjugates for Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Antibody-drug Conjugates for Tumors players cover Roche（Genentech）, Daiichi Sankyo, GSK, Rakuten Medical, ADC Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Antibody-drug Conjugates for Tumors Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates for Tumors sales in 2025, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates for Tumors sales for 2026 through 2032. With Antibody-drug Conjugates for Tumors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates for Tumors industry.
This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates for Tumors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody-drug Conjugates for Tumors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-drug Conjugates for Tumors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates for Tumors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates for Tumors.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates for Tumors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
DNA Damaging Drugs
Tubulin Inhibitors
Other
Segmentation by Application:
Hematological Tumors
Solid Tumors
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Roche（Genentech）
Daiichi Sankyo
GSK
Rakuten Medical
ADC Therapeutics
RemeGen
AbbVie(ImmunoGen)
Pfizer（Seagen)
Takeda
Gilead Sciences
AstraZeneca
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antibody-drug Conjugates for Tumors market?
What factors are driving Antibody-drug Conjugates for Tumors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antibody-drug Conjugates for Tumors market opportunities vary by end market size?
How does Antibody-drug Conjugates for Tumors break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
113 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Antibody-drug Conjugates for Tumors by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Antibody-drug Conjugates for Tumors by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
